leadf
logo-loader
viewAequus Pharmaceuticals Inc.

Aequus extends commercial agreement with Sandoz for transplant therapy tacrolimus in Canada

CEO Doug Janzen sees considerable room for growth over the next 12 months for tacrolimus, as Aequus plans continued support for patients and physicians

Aequus Pharmaceuticals Inc. - Aequus extends commercial agreement with Sandoz for transplant therapy tacrolimus in Canada
The Vancouver-based company said it has extended its commercial agreement on tacrolimus with Sandoz Canada Inc to December 31, 2021

Aequus Pharmaceuticals Inc (CVE:AQS) (OTCQB:AQSZF) (FRA:AEQ) said on Friday that it has agreed to an extension of terms for its promotional service agreement on the Sandoz drug tacrolimus immediate-release (tacrolimus IR), which is used to prevent patient rejection after organ transplants. 

The Vancouver-based company said that it has extended its commercial agreement on tacrolimus with Sandoz Canada Inc to December 31, 2021. A trio of drugs including tacrolimus currently form the core of the Canadian company’s business. 

In December 2015, Aequus said it began promoting Sandoz’s generic tacrolimus, a transplant therapy which aims to treat and prevent acute rejection following an organ transplant. Tacrolimus has since achieved “over 10x growth” in Canada through increased brand awareness and new patient adoption programs, according to the company.

READ: Aequus Pharmaceuticals has the right Rx to bring new drugs to the Canadian market

“We believe there continues to be considerable room for growth over the next 12 months for tacrolimus IR, as we plan continued support for patients and physicians regarding the use of this high-quality and cost-effective alternative to branded tacrolimus,” Aequus Pharmaceuticals CEO Doug Janzen said in a statement.  

Janzen said the extension is “particularly meaningful” as it reaffirms Aequus’ commercial capabilities across specialties, “from market access and reimbursement to sales force execution,” which is a key driver of growth in the pharma business.

“Sandoz has been a fantastic partner and while we continue to talk to them about Vistitan and other potential products, this extension allows us to seamlessly continue our efforts on Tacrolimus IR while our Eye Care team focus on the launches of the Evolve products,” added Janzen.

Vistitan, which reduces the pressure inside the eyes of patients with glaucoma was first marketed by the pharma giant Sandoz.

Medicom’s Evolve line of preservative-free, dry-eye products is a preservative-free prescription product for the treatment of open-angle glaucoma.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Quick facts: Aequus Pharmaceuticals Inc.

Price: 0.115 CAD

TSX-V:AQS
Market: TSX-V
Market Cap: $12.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Aequus Pharmaceuticals Inc. named herein, including the promotion by the Company of Aequus Pharmaceuticals Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Aequus Pharmaceuticals receives approval for Evolve Gel lubricating eye...

Aequus Pharmaceuticals (CVE: AQS- OTCQB: AQSZF) CEO Doug Janzen joined Steve Darling from Proactive Vancouver with news the company has been granted a medical device licence for Evolve Intensive Gel. This product is a preservative free treatment for moderate to severe forms of dry-eye...

2 days, 10 hours ago

2 min read